35 results about "Adhesion factor" patented technology

The invention provides a tissue repair support and its preparation method and use. The tissue repair support comprises a porous tridimensional network structure composed of a composite fiber layer and a hydrophilic material. The composite fiber layer comprises composite fibers composed of an adhesion factor and a hydrophobic synthesis material. The tissue repair support is used for meninge repair, spinal meninge repair, a tissue engineering support material, artificial skin, a wound accessory material, a biomembrane, a wound cladding material, a haemostasis material, a postoperative antistick material or a beauty treatment material.

The invention provides a carrier barrier system applied to the prevention and treatment of metrosynizesis. The carrier barrier system consists of a cervix uteri conformable stuffing injection device and an injected carrier barrier material, wherein the cervix uteri conformable stuffing injection device is formed by connecting a lossless guiding bulb, an endocervical medicinal injection port, blocking sacculus, a double-cavity catheter and a carrier barrier injection port sequentially; and a sacculus injection branch opening is also formed at the position close to the carrier barrier injection port on the double-cavity catheter. The carrier barrier system is characterized in that the blocking sacculus is arranged outside a cervical orifice; the carrier barrier material is a colloid material which can be degraded and absorbed by human bodies; and by the carrier barrier system, the high isolation of uterine cavities can be realized, the concentration of adhesion factors can be reduced, and the regeneration and repair of endometria can be promoted.

The invention relates to a vehicle curve safety vehicle speed predication and pre-warning system based on multiple regression analysis. The vehicle curve safety vehicle speed predication and pre-warning system based on the multiple regression analysis comprises a test data collection module, a test data pre-processing module, a test data analysis module, a safety vehicle speed model database, a curve information module, a vehicle type judging module and a curve safety vehicle speed pre-warning module. According to the vehicle curve safety vehicle speed predication and pre-warning system basedon the multiple regression analysis, desired test data are collected, multiple linear regression analysis is carried out on processed test data to obtain a critical transverse adhesion factor model and a transverse load transfer rate model, and the critical transverse adhesion factor model and the transverse load transfer rate model are converted by using a formula to obtain a safety vehicle speedmodel. Collected curve pavement data and vehicle types are input into the safety vehicle speed model database. A curve safety predicated vehicle speed is obtained after calculation and displayed on an LED display screen at the entrance of a curve to warn a driver of a curve safety passing vehicle speed. According to the vehicle curve safety vehicle speed predication and pre-warning system based on the multiple regression analysis, the influences of multiple factors on the curve safety vehicle speed are comprehensively considered, and the curve safety vehicle speed can be accurately predicatedto provide a safety pre-warning vehicle speed for the driver so that the vehicle stably and safely runs through the curve.

The invention relates to a simulation method for traction control of a rail vehicle. The simulation method for traction control of the rail vehicle comprises a wheel speed of the vehicle to change as a first input of the simulation, an adhesion factor of a rail surface to change as a second input of the simulation and an output which is a calculated motor load torque and/or a vehicle speed according to the a vehicle tractive load model, wherein the tractive load model comprises a force transmission model considering an interaction between wheels and rails. The simulation method for traction control of the rail vehicle is suitable for a simulation application of traction control of a motor train unit, a metro and an inter-city train.

The invention discloses a cascade sliding-mode observer and an adhesion factor and derivative estimation method. The cascade sliding-mode observer comprises a load torque observer and a load torque derivative observer; firstly a dynamical model for the operational process of a heavy load locomotive is created, a state equation for an adhesion control system is created according to a motor torque balance equation, a scheme for estimating the adhesion factor by a load torque is proposed, then the cascade sliding-mode observer is designed, the stability of the cascade sliding-mode observer is proved with the help of a Lyapunov stability theory, and then a sliding mode variable structure equivalence control principle is utilized to create an algorithm for estimating the adhesion factor and a derivative. The direct differential computation of a signal is avoided, the derivative of the load torque is estimated according to the sliding mode variable structure equivalence principle, and a method for inhibiting the buffeting of the sliding-mode observer is provided; the algorithm is simple and easy to implement; an observation value and an actual value are matched through simulation and experiments, and the effectiveness of the algorithm is verified.

Provided in the invention is a tip of an atomic force microscope probe. The probe tip is characterized in that: the tip comprises: a helicobacter pylori; a gold particle layer covered on the outer surface of the helicobacter pylori; and a helicobacter pylori adhesion factor modified on the outer surface of the gold particle layer. Besides, the invention also provides an atomic force microscope probe including the tip as well as a method for detecting capability of adhesion between helicobacter pylori and gastric mucus. According to the invention, on the basis of atomic force microscopy (AFM), a condition of contact between helicobacter pylori and gastric mucus in a natural state is substantially simulated by utilizing characteristics of high precision and real-time observation of the AFM, so that it becomes possible to carry out on-site research on a submicron acting force between an adhesion factor and the gastric mucus in the scale of micron meters; and mechanical information that is obtained by utilizing a force curve is converted into adhesive work according to a formula, thereby carrying out accurate quantification on the capability of adhesion between the adhesion factor on the surface of the helicobacter pylori and the gastric mucus.

The invention discloses a method for preparing a pneumonia rat model and a model evaluation method, and belongs to the technical field of biology. The method for establishing the pneumonia rat model is non-invasive and safe to rats, does not damage other organs of rats in the whole process, and effectively avoids the death of the rats. Besides, the method has simple operation and high success rate. According to the pneumonia rat model established by the method, pseudomonas aeruginosa in bronchoalveolar lavage fluid is obviously increased, inflammatory factors IL-4 and TNF-alpha are obviously increased, the level of adhesion factor IFN-gamma is obviously reduced, and the number of leukocytes is obviously increased. Meanwhile, the lung index is also obviously increased, which indicates thatthe model is established well.

The invention discloses a biologic compound preparation capable of increasing weight and reducing feed conversion rate, for raising waterfowls. The biologic compound preparation is characterized by comprising the following components in percentage by mass of 50-55% of soluble glucose, 1-4% of enterococcus faecium, 0.5-2% of bacillus subtilis, 10-20% of bacillus coagulans, 3-10% of clostridium butyricum, 1-5% of adhesion factors, and 15-30% of composite immunoglobin for animals, wherein the enterococcus faecium, the bacillus subtilis, the bacillus coagulans, the clostridium butyricum and the adhesion factors are made into bacterium powder through performing coating treatment on bacterium fermentation liquor, and the viable count of the coated bacterium powder includes that the viable count of the enterococcus faecium is (1500-2500)*10<8>CFU/g, the viable count of the bacillus subtilis is (4500-5500)*10<8>CFU/g, the viable count of the bacillus coagulans is (30-50)*10<8>CFU/g, the viable count of the clostridium butyricum is (90-100)*10<8>CFU/g, and the viable count of the adhesion factors is (40-60)*10<8>CFU/g.

An electrolytic copper foil capable of securing a secondary battery having a high capacity retention rate, an electrode including the same, a secondary battery including the same, and a method of manufacturing the same. The electrolytic copper foil, which includes a first surface and a second surface opposite to the first surface, includes a copper layer including a matte surface facing the first surface and a shiny surface facing the second surface, and a first protective layer on the matte surface of the copper layer, wherein the first protective layer includes chromium (Cr) and the first surface of the electrolytic copper foil has an adhesion factor of 1.5 to 16.3.

The present invention provides bee venom which can decrease expression levels of sclerotic factors, inflammatory factors and vascular adhesion factors associated with atherosclerosis, and a pharmaceutical composition comprising the bee venom as an active ingredient for the treatment of the atherosclerosis. When the bee venom was administered to laboratory animal models of atherosclerosis, the total cholesterol and neutral lipid were decreased, high-density cholesterol was maintained or even increased, the expression levels of TNF-α and IL-β as inflammation-associated cytokines were decreased in the blood, the expression levels of fibrosis-associated cytokines and vascular adhesion factors were decreased in the main artery and the heart, the plaque deposition generally caused by the atherosclerosis was decreased, and the expression levels of intercellular adhesion molecules (ICAM) and vascular cell adhesion molecules (VCAM), TGF-β1 and fibronectin as fibrosis-related cytokines were decreased.

Preactivated and disaggregated shape-changed platelets, fixed shape-changed platelets, and a pharmaceutical composition thereof are used for treating acute and emergent inflammatory disease in a dosage of 1×10⁶ to 1×10⁸. Activated platelets release and transfer adhesion factors to the surface of platelet cells, and trap stromal vascularity inflammatory cells from inflammated and damaged place, and the stromal vascularity inflammatory cells are eliminated through the circulatory system to alleviate inflammation. The fixed shape-changed platelets are able to alleviate inflammation and sustainable for longer storage duration.

The invention relates to a TNF alpha and DC-SIGN fusion protein and an application thereof. In a traditional anti-tumor medicament or a treatment method, normal cells are easy to damage in the process of killing tumor cells. The targeting anti-tumor fusion protein provided by the invention comprises an identification functional domain and an action functional domain, as well as a connecting peptide for connecting the two functional domains. The identification functional domain is as follows: a lectin polypeptide with tumor cell surface sugar chain identification and combination functions-a DC surface specific intercellular adhesion factor 3 combined with non-integrin molecules (DC-SIGN, dendritic-cell-specific ICAM-3-grabbing nonintegrin) is positioned at a C terminal of the fusion protein; the action functional domain is as follows: a tumor necrosis factor (TNF) is positioned at an N terminal of the fusion protein; and the connecting peptide is a short peptide containing 8-25 amino acids. The fusion protein can utilize lectin and cancer cells to perform targeting combination, induce the apoptosis of the cancer cells through a ligand capable of promoting the apoptosis of the cells and simultaneously reduce the killing effect against normal tissues and cells.

An abrasive cutting tool includes a body in a shape of a large diameter disk having an outer diameter of at least about 60 centimeters. The body has an aspect ratio defined as a ratio (D:T) between the outer diameter to an axial thickness of the body of at least about 10:1. The body includes an abrasive portion having a bond material and abrasive particles contained within the bond material. The abrasive portion also includes a first filler having iron and sulfur with an average particle size of not greater than about 40 microns. The body also includes a reinforcing member and a Thermal Adhesion Factor (TAF) of at least about 30%.

It is intended to provide a method whereby the skin conditions (for example, loss in the skin elasticity, wrinkle formation possibility, insufficient tightness in dermal collagen fiber bundles, or the like) can be exactly and conveniently assessed. It is also intended to provide a method whereby the wrinkle-improvement effect of a test substance can be exactly and conveniently evaluated. The skin conditions are assessed by using the expression amount of an adhesion factor in skin cells as an indication. The wrinkle reducing effect of a test substance is evaluated by using the expression amount of an adhesion factor in skin cells in the presence of the test substance as an indication.

The present invention provides a new cell wall adhesion factor CaFlo11 protein of candida albicans, polynucleotide for coding CaFlo11 protein and method for producing this CaFlo11 protein by utilizing recombination technique. Besides, said invention also provides application of polynucleotide for coding said CaFlo11 protein. In the saccharomyces cerevisiae the high-expression CaFlo11 gene can raise adhesion between yeast cells, and can promote formation of flocculent precipitate, at the same time can give the capability to saccharomyces cerevisiae cells and make them be adhered on the gelatin, so that said CaFlo11 is a good cell wall adhesion factor.